Table 1.
Baseline demographic and clinical characteristics
| IFX-1 group (n=15) | Control group (n=15) | ||
|---|---|---|---|
| Age, years | 58 (9) | 63 (8) | |
| Gender | |||
| Female | 4 (27%) | 4 (27%) | |
| Male | 11 (73%) | 11 (73%) | |
| Race | |||
| Asian | 5 (33%) | 2 (13%) | |
| Black | 2 (13%) | 2 (13%) | |
| White | 8 (53%) | 11 (73%) | |
| Median time from symptom onset to randomisation, days | 11 (7–12) | 13 (9–14) | |
| Median time from COVID-19 diagnosis to randomisation, days | 2 (0–4) | 2 (1–4) | |
| Number of risk-relevant coexisting conditions | |||
| None | 4 (27%) | 6 (40%) | |
| One | 7 (47%) | 8 (53%) | |
| Two or more | 4 (27%) | 1 (7%) | |
| Selected coexisting conditions | |||
| Hypertension | 6 (40%) | 3 (20%) | |
| Diabetes | 4 (27%) | 4 (27%) | |
| Obesity | 2 (13%) | 4 (27%) | |
| Intubated at randomisation | 8 (53%) | 10 (67%) | |
| Intubated within 6 h of randomisation* | 2 (13%) | 0 | |
| Oxygen mask | 6 (40%) | 2 (13%) | |
| Nasal cannula | 1 (7%) | 3 (20%) | |
| Admission department at randomisation | |||
| Intensive care unit | 8 (53%) | 10 (67%) | |
| Intermediate care unit | 5 (33%) | 2 (13%) | |
| COVID-19 ward | 2 (13%) | 3 (20%) | |
| Standard-of-care medications | |||
| Chloroquine | 7 (47%) | 5 (33%) | |
| Ganciclovir | 1 (7%) | 0 | |
| Azithromycin | 1 (7%) | 0 | |
| Nadroparin | 15 (100%) | 14 (93%) | |
| Heparin | 5 (33%) | 8 (53%) | |
| Acetylsalicylic acid | 4 (27%) | 4 (27%) | |
| Apixaban | 2 (13%) | 2 (13%) | |
| Rivaroxaban | 1 (7%) | 3 (20%) | |
| Clopidogrel | 1 (7%) | 2 (13%) | |
| Tinzaparin | 1 (7%) | 2 (13%) | |
| Carbasalate | 0 | 2 (13%) | |
| Dabigatran | 0 | 1 (7%) | |
| Edoxaban | 1 (7%) | 0 | |
Data are n (%), mean (SD), or median (IQR).
*
Additional patients intubated after baseline.